Prospective observational study to predict sensitive marker after administration of nintedanib in patients with idiopathic pulmonary fibrosis

Trial Profile

Prospective observational study to predict sensitive marker after administration of nintedanib in patients with idiopathic pulmonary fibrosis

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 28 May 2016

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Pulmonary fibrosis
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 28 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top